
Vera Therapeutics (VERA) Stock Forecast & Price Target
Vera Therapeutics (VERA) Analyst Ratings
Bulls say
Vera Therapeutics is well positioned by Trutakna’s unexpectedly strong early launch, with $10.3M in 3Q26 net sales versus $4.0M consensus and about 700 patient start forms since July 7, indicating accelerating real-world demand in a large IgAN market. Its fundamental case is reinforced by ORIGIN 3 data showing a 5.00 mL/min/1.73 m²/yr eGFR slope advantage, 5.1% versus 17.8% kidney-disease progression, and no dialysis, transplant, or death events on Trutakna, supporting the sBLA and potential full approval by mid-2027. With approximately $384M in cash, cash equivalents, and marketable securities at the end of 3Q26, plus a pathway to 50% covered lives by year-end, the company appears financially capable of funding commercialization while converting early launch momentum into durable revenue.
Bears say
Vera Therapeutics is facing a negative setup because Trutakna’s early $10M first-quarter revenue and 700 patient start forms still leave commercial traction difficult to gauge, while another IgAN competitor could launch in December and pressure uptake. The company also expects higher cost of goods sold at 15%-20% from 4Q26 onward due to royalty payments to Merck KGaA, which could weigh on margins as R&D and SG&A remain elevated. Although it ended 3Q 2026 with $384M in cash and later drew $75M, it is not expected to be profitable until 2029 and may need additional capital, creating dilution risk.
This aggregate rating is based on analysts' research of Vera Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vera Therapeutics (VERA) Analyst Forecast & Price Prediction
Start investing in Vera Therapeutics (VERA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Vera Therapeutics (VERA) Forecast
Vera Therapeutics (VERA) Analyst Forecast & Price Prediction
Start investing in Vera Therapeutics (VERA)
Order type
Buy in
Order amount
Est. shares
0 shares